To determine whether this previously defined new pathway of GSLC radioresistance involving FGFR1, FOXM1, MELK, GLI2, TWIST1 and ZEB1 may be crucial for the in vivo GBM response to the standard treatment associating surgery and radio-chemotherapy, we investigated whether the associated expression of these six genes may be predictive of overall survival for patients treated with chemo-radiotherapy protocol. The gene discussed is TWIST1; the disease is glioblastoma.